NCT00141531View on ClinicalTrials.gov

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Bladder Neoplasms

Interventions

DRUG

Apaziquone

"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."

Trial Locations (1)

Unknown

St Radboud University Hospital, Nijmegen

All Listed Sponsors

lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT00141531 - Phase II Trial of EOquin in High-risk Superficial Bladder Cancer | Biotech Hunter | Biotech Hunter